Background Analysis: US FDA Advisory Committee to Discuss Communication of Fetal Effects of Methadone or Buprenorphine for Opioid Addiction – JUN 8-9, 2015 (RCAC)
The US FDA has scheduled a Risk Communications Advisory Committee (RCAC) meeting for Monday and Tuesday, June 8-9, 2015. The Committee will discuss approaches to communicating information about fetal effects in product labeling for methadone or buprenorphine maintenance therapy for opioid addiction, and about the maternal benefits and risks of treatment, to best enable patients and healthcare providers to make informed decisions about the use of these drugs during pregnancy.